EDNRA and neoplasm: Of note macitentan, a dual ETAR/ETBR antagonist, may also obstacle the tumor progression targeting cells within the TME expressing both ETAR and ETBR, including stromal and immune cells [10, 40], which makes it an alternative treatment against metastatic dissemination in HG-SOC.